Published in Cellular Signalling, researchers from Kunming Medical University report new evidence that cannabidiol (CBD) may help reduce key drivers of methamphetamine-related neurotoxicity.
Their findings center on the sigma-1 receptor (S1R), a chaperone protein that appears to play a central role in methamphetamine-induced cellular damage.
The team replicated methamphetamine’s known effects on oxidative stress and autophagy in both HT22 neuronal cells and in C57BL/6J mice. Across models, methamphetamine exposure caused a marked increase in S1R expression, which the researchers found contributed directly to elevated oxidative stress and abnormal autophagy.
When S1R was inhibited, through a chemical blocker, gene knockdown, or full knockout, those harmful effects were significantly reduced.
CBD produced similar protective outcomes. The study found that CBD lowered the methamphetamine-induced spike in S1R expression and, in turn, reduced oxidative stress and excessive autophagy in cell and animal models. The authors note that this dual action positions S1R as a promising therapeutic target and suggests CBD may have clinical potential for mitigating the neurological damage associated with methamphetamine use disorder.
Overall, the research highlights a novel mechanism underlying methamphetamine toxicity and provides early evidence that CBD could help counteract those effects by suppressing S1R-linked pathways.
More articles from The Marijuana Herald can be found below.
